--- title: 'Senior Scientist, Lentiviral Vector Cell Line Development at Asimov' canonical: 'https://feeny.ai/job/senior-scientist-lentiviral-vector-cell-line-development-asimov-boston-fdjvx16748gc' type: 'job' last_seen: '2026-10-16' --- # Senior Scientist, Lentiviral Vector Cell Line Development at Asimov - **Company:** Asimov - **Location:** Boston, MA - **Compensation:** $145k–$165k - **Employment:** full-time - **Work type:** onsite - **Posted:** 2026-09-22 - **Last confirmed live:** 2026-10-16 - **Apply:** https://jobs.ashbyhq.com/asimov/f36c97dc-eed9-4e69-9d4b-67a3f6ab65cb ## Job description Our mission at Asimov is to advance humanity's ability to design living systems, enabling biotechnologies with outsized benefit to society. We are developing a mammalian synthetic biology platform––from cells to software––to enable the design and manufacture of next-generation therapeutics. We are hiring a Senior Scientist to lead our Lentiviral Vector Cell Line Development team in Boston, MA. This role blends strategic leadership with hands-on experimentation, giving you direct influence over our Lentiviral Vector platform roadmap and scientific vision. You will drive the creation of stable producer cell lines for lentiviral vector therapeutics while innovating next-generation cell line development workflows. This is a unique opportunity to work at a nimble, forward-thinking synthetic biology startup and help build the future of biological engineering. About the Role: - Set and steer the scientific roadmap for the Lentiviral Vector cell line development (CLD) platform. - Perform lentiviral vector stable producer cell line development processes including transfection, pool generation, single cell cloning, clone screening and characterization, and cell banking using state-of-the-art equipment. - Serve as the primary Lentiviral Vector CLD technical contact on customer and commercial projects. Partner with our commercial team to present platform capabilities to prospective partners and translate customer requirements into executable CLD project plans. - Provide technical leadership and mentorship to scientists on the team, including managing direct report(s) and setting a high bar for experimental design, data analysis and record-keeping. - Represent Lentiviral Vector CLD on cross-functional and leadership-facing project teams, making calls on cell line development strategy and clearly communicating progress, risk and plans. - Support innovation through development of novel workflows and applications - Support research projects to develop viral vector production methods to enhance product quality attributes such as empty/full ratio, potency and/or cell targeting. - Work effectively as part of a cross-functional team in support of a Lentiviral Vector CLD platform and in collaboration with Synthetic Biology and Process Development teams. - Design experiments, analyze data, troubleshoot, and maintain detailed records. - Represent Lentiviral Vector CLD on project teams, making decisions for cell line development activities and effectively communicating results, progress and plans. - Represent Asimov's science externally through publications and presentations at leading industry conferences. About You: - M.S. or PhD in Biological Engineering, Virology, Cell Biology, Molecular Biology, or a related field. - 7+ years of hands-on experience in biopharma, including 4+ years focused on lentiviral vector producer or packaging cell line development in support of GLP or GMP production of cell or gene therapies. - 2+ years of experience managing direct report(s) and providing technical guidance. - Proven track record balancing hands-on bench leadership with big-picture platform strategy and roadmapping. - Experience communicating technical work to external stakeholders and translating their needs into technical plans. - Demonstrated ability to communicate scientific work externally, evidenced by publications, patents, and/or conference presentations. - Experience with downstream purification and PQ assessment of lentiviral vectors, T-cell transduction assay, viral genome engineering, and/or host cell genome engineering related to virus production or producer cell line technologies is highly desired. - Experience with process development at Ambr or benchtop bioreactor scale is a plus. - Comfortable working with large, multidimensional datasets and applying statistical or computational methods to extract actionable biological or process insights. - Strong written and verbal communication skills required. We're fueled by a vision to transform biological engineering into a fully-fledged engineering discipline. Should you join our team, you will grow with a constantly evolving organization and push the frontiers of synthetic biology. Company culture is key to Asimov, and ours is a culture of recombination; we believe that our mission can only be achieved by bringing together a diverse team with a mixture of backgrounds and perspectives. ## About Asimov ## Company Overview - **One-liner**: Asimov builds an integrated platform of cells, genes, and software to program living systems, enabling the design and manufacture of advanced therapies. - **Entity Type**: Private (Series B, raised $175M in January 2023) - **Headquarters**: Boston, Massachusetts, USA (with a second office in Boulder, Colorado) - **Founded**: 2017 - **Founders**: Alec Nielsen (CEO), Chris Voigt, Doug Densmore, Raja Srinivas ## Core Business - **Primary industry/industries**: Synthetic biology, biotechnology, therapeutics manufacturing - **Target customers**: B2B – biotech startups, mid-size biotechs, and large pharmaceutical companies (partnered with over 25 companies) - **Mission or purpose statement**: “To radically advance humanity’s ability to design living systems, enabling biological technologies with outsized societal benefit.” ## Products & Services - **Design Software**: Cloud-based CAD platform to design, simulate, and optimize genetic systems in different cell types. - **Genetic Parts Library**: Over 1,000 experimentally validated genetic parts (transposases, expression vectors, inducible systems, tissue-specific promoters, etc.). - **Host Cell Lines**: Engineered, highly characterized GMP host cells for therapeutic production (CHO, HEK293, etc.) with regulatory documentation. - **LV Edge**: Stable cell lines and software tools for lentiviral titers up to 1E9 TU/mL. - **AAV Edge**: End-to-end payload design and production achieving titers up to 6E15 vg/L. - **RNA Edge**: Sequence design through wet-lab validation in weeks. - **CHO Edge**: Genetic tools and data-driven models delivering titers of 8–12 g/L across modalities. - **Platform Transfer & Full Service**: Two engagement models – customers use the platform in-house, or Asimov performs cell line development and process development at its Boston lab. ## Market Standing - **Valuation/Market Cap**: Not disclosed - **Key Metric**: Total funding of $205M; annual revenue of ~$4.0M (LinkedIn estimate) - **Notable Investors/Partners**: Andreessen Horowitz (seed lead), Horizons Ventures (Series A lead), CPP Investments (Series B lead), DARPA (research support). Partners include 25+ biotechs and pharma companies. - **Growth Signals**: 95 employees (25.8% YoY growth); raised $200M in Series B (Jan 2023); launched AI-driven 4th generation CHO Edge System with increased titer guarantee; expanding into RNA and cell therapy tools. ## Competitive Advantages - Only company offering an end-to-end platform that integrates mammalian synthetic biology, computer-aided design, and machine learning. - Proprietary library of 1,000+ well-characterized genetic parts and GMP-banked host cells. - “We use our own platform every day” – internal R&D teams validate improvements before releasing to customers. - Strong regulatory support (GMP documentation for host cells) that de-risks therapeutic development. ## Strategic Focus - Deepen AI/ML integration into genetic design and cell line development. - Expand platform to cover more therapeutic modalities (cell therapy, RNA therapy, biologics). - Scale partnerships with large pharma while continuing to support early-stage biotechs. - Build out the “first CAD platform for biology” to transition genetic engineering into a fully-fledged engineering discipline. ## Why Work Here - **Culture**: “A culture of recombination” – interdisciplinary team of biologists, engineers, and ML scientists. Values include mission first, urgency, continuous learning, thoughtful communication, and avoiding local optima. - **Work model**: Hybrid – employees engage in a combination of remote and on-site work (Cambridge, MA and Boulder, CO). - **Perks & growth**: Built In profile highlights career growth, compensation & benefits, work-life balance, and stability. The company is actively hiring across roles (Staff Software Engineer, Principal Scientist, Sr. Scientist, Associate Director). - **Impact**: Work at the cutting edge of synthetic biology, directly contributing to the design and manufacture of life-saving therapies. ## Sources 1. [asimov.com](https://www.asimov.com/) 2. [asimov.com/about](https://www.asimov.com/about) 3. [LinkedIn](https://www.linkedin.com/company/asimov) 4. [Built In](https://builtin.com/company/asimov) 5. [Careers Page](https://jobs.ashbyhq.com/asimov) ## Other roles at Asimov - [Scientist, Viral Vector Process Development](https://feeny.ai/job/scientist-viral-vector-process-development-asimov-boston-1qsqy03f8zyb) — Boston, MA - [Scientist, Lentiviral Vector Cell Line Development](https://feeny.ai/job/scientist-lentiviral-vector-cell-line-development-asimov-boston-vhtpf4a8bt9m) — Boston, MA - [Senior Scientist, Analytical Development](https://feeny.ai/job/senior-scientist-analytical-development-asimov-boston-9r1y790704fx) — Boston, MA - [Senior Program Manager](https://feeny.ai/job/senior-program-manager-asimov-boston-9pe8sjrfnxdw) — Boston, MA - [Principal Scientist, Biologics Cell Line Development](https://feeny.ai/job/principal-scientist-biologics-cell-line-development-asimov-boston-zc098zf7xer4) — Boston, MA - [Senior Scientist, Biologics Cell Line Development](https://feeny.ai/job/senior-scientist-biologics-cell-line-development-asimov-boston-5ypxr524ze78) — Boston, MA